Therapy for Early COVID-19: A Critical Need.

  title={Therapy for Early COVID-19: A Critical Need.},
  author={Peter S Kim and Sarah W. Read and Anthony S. Fauci},
While coronavirus disease 2019 (COVID-19) is predominantly self-limited, up to 20% of symptomatic individuals will progress to severe or critical disease with clinical manifestations including pneumonia, acute respiratory distress syndrome, multiorgan system dysfunction, hypercoagulation, and hyperinflammatory manifestations. There have been more than 47 million cases of COVID-19 globally resulting in more than 1.2 million deaths. Additionally, a growing body of data suggests that some patients… 
Increased Gal-3BP plasma levels in hospitalized patients infected with SARS-CoV-2
  • Valentina Gallo, Ana André Carolina Cláudia Claudia Carolina S. Helena Reis Miranda Martins Serre-Miranda Nobrega Silva S, S. Iacobelli
  • Medicine, Biology
    Clinical and Experimental Medicine
  • 2022
Gal-3BP plasma levels were measured retrospectively in a cohort of 84 hospitalized COVID-19 patients and, as expected, patients with severe disease had plasma levels of IL-6 higher than patients with non-severe disease.
Therapeutic Application of Alpha-1 Antitrypsin in COVID-19
The aim of this study was to investigate whether AAT can be considered as a candidate for the treatment of COVID-19, and found that AAT inhibits the protease activity in a concentration between 1 and 5mg/ml in submersed, undifferentiated epithelial cells or organoids.
Cardiovascular Injury Due to SARS-CoV-2
During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury.
Addressing the ‘hypoxia paradox’ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues
Substitution of erythropoietin might overcome this ‘hypoxia paradox’ caused by deranged signaling and improve survival/functional status of COVID-19 patients and their long-term outcome and a double-blind, placebo-controlled, randomized clinical trial is warranted.
The time to offer treatments for COVID-19
The call on public health authorities to authorize treatments with known low-risk and possible benefit for outpatients in parallel with universal vaccination is called on.
Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications
Evidence suggests that the fatalities associated with COVID-19 are primarily due to hyper-inflammation and an aberrant immune function, and the magnitude of the release of pro-inflammatory cytokines such as interleukin (IL)-1, (IL-6), and tumor necrosis alpha (TNF-α) significantly differentiate between mild and severe cases of CO VID-19.
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection
Therapeutic approaches and vaccination in fighting COVID-19 infections: A review
Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review


Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Remdesivir for the Treatment of Covid-19 — Final Report
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11.
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
A prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19 found that low-dose dexamethasone reduced mortality in hospitalized patients with Cohen's disease who required respiratory support.
Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic.
This webinar series will address specific health care facility measures based on immediate, short- and long-term needs regarding preplanning, inspection, testing and maintenance, sustainability and the 'new normal' in the COVID-19 pandemic.
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial
In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19.
Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients